Cargando…
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
OBJECTIVES: Recent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralises IL-4/IL-13 making it ideal for explorat...
Autores principales: | Allanore, Yannick, Wung, Peter, Soubrane, Christina, Esperet, Corinne, Marrache, Frederic, Bejuit, Raphael, Lahmar, Amel, Khanna, Dinesh, Denton, Christopher P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677494/ https://www.ncbi.nlm.nih.gov/pubmed/32963047 http://dx.doi.org/10.1136/annrheumdis-2020-218447 |
Ejemplares similares
-
Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019) -
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019) -
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019) -
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023) -
Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)